Form 4 for BEAM Beam Therapeutics Inc.
Accepted 2026-04-01 18:32:14 ET · period of report 2026-03-30 · accession 0001193125-26-138348 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-04-01 18:32 | 2026-03-30+ | BEAM | Evans John M. | CEO, Dir | M - OptEx | $0.67 | +50.0K | 1.01M | +5% | +$33.5K |
| DMT | 2026-04-01 18:32 | 2026-03-30+ | BEAM | Evans John M. | CEO, Dir | S - Sale+OE | $22.57 | -50.0K | 986.7K | -5% | -$1.13M |
| DT | 2026-04-01 18:32 | 2026-03-31 | BEAM | Evans John M. | CEO, Dir | A - Grant | $0.00 | +90.0K | 1.08M | +9% | $0 |
| DMT | 2026-04-01 18:32 | 2026-03-30+ | BEAM | Evans John M. | CEO, Dir | M - OptEx | $0.00 | -50.0K | 18.7K | -73% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-30 | M | A | 25,000 | $0.67 | 1,011,667 | D | — | — | (F1) These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. |
| 2 | Common | Common Stock | 2026-03-30 | S | D | 25,000 | $22.37 | 986,667 | D | — | — | (F1) These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $22.03 to $22.70, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 3 | Common | Common Stock | 2026-03-31 | M | A | 25,000 | $0.67 | 1,011,667 | D | — | — | (F1) These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. |
| 4 | Common | Common Stock | 2026-03-31 | S | D | 25,000 | $22.76 | 986,667 | D | — | — | (F1) These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $22.34 to $23.21, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 5 | Common | Common Stock | 2026-03-31 | A | A | 90,000 | $0.00 | 1,076,667 | D | — | — | (F4) Represents restricted stock units ("RSUs") granted to the Reporting Person under the BEAM 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date. |
| 6 | Derivative | Stock Option (Right to Buy) | 2026-03-30 | M | D | 25,000 | $0.00 | 43,672 | D | $0.67 · — to 2028-05-08 | 25,000 Common Stock | (F1) These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. (F5) On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,396 shares upon the achievement of a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 99,336 shares. |
| 7 | Derivative | Stock Option (Right to Buy) | 2026-03-31 | M | D | 25,000 | $0.00 | 18,672 | D | $0.67 · — to 2028-05-08 | 25,000 Common Stock | (F1) These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. (F5) On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,396 shares upon the achievement of a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 99,336 shares. |